Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with SARS-CoV-2 directed vaccins.
Conditions
Interventions
Trade Name: BNT162b2
Product Name: BNT162b2
Product Code: EMEA/H/C/005735
Pharmaceutical Form:
Trade Name: mRNA-1273
Product Name: mRNA-1273
Product Code: EMEA/H/C/005791
Pharmaceutical Form: Soluti
Sponsors
Fachhochschule Salzburg GmbH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - written consent to participate in this study - persons aged 18 and older (adults) - from 2 up to 9 months after receiving a vaccination or going through a Covid-19 disease (as confirmed by PCR) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1950 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50
Exclusion criteria
Exclusion criteria: - No consent - Persons below 18 years of age - Persons without vaccination or who did not have Covid-19 - Persons who do not speak or understand the German language
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To discover potential differences between vaccins in their capability to induce antibody production in humans due to factors such as body weight, age and pre-existing diseases. ;Secondary Objective: Not applicable;Primary end point(s): SARS-CoV-2-spcific IgG antibodies;Timepoint(s) of evaluation of this end point: Directly after the time of drawing blood, analysis will be performed on the same day | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable | — |
Countries
Austria
Contacts
Public ContactClinical Study Information
Fachhochschule Salzburg GmbH
Outcome results
None listed